Biologically safe transient protein expression in plants

Details for Australian Patent Application No. 2005259335 (hide)

Owner Icon Genetics GmbH

Inventors Marillonnet, Sylvestre; Muhlbauer, Stefan; Werner, Stefan; Engler, Carola; Gleba, Yuri; Herz, Stefan; Klimyuk, Victor

Agent Spruson & Ferguson

Pub. Number AU-B-2005259335

PCT Pub. Number WO2006/003018

Priority 60/593,454 15.01.05 US; 04 016 011.1 07.07.04 EP

Filing date 7 July 2005

Wipo publication date 12 January 2006

Acceptance publication date 27 August 2009

International Classifications

A01H 5/12 (2006.01) Products - Leaves

C12N 15/74 (2006.01) Mutation or genetic engineering - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

C12N 15/82 (2006.01) Mutation or genetic engineering - for plant cells

Event Publications

4 January 2007 PCT application entered the National Phase

  PCT publication WO2006/003018 Priority application(s): WO2006/003018

19 April 2007 Assignment before Grant

  Icon Gentics AG The application has been assigned to Icon Gentics GmbH

5 July 2007 Corrigenda

  Assignments Before Grant, Section 113 - 2005 Under the name Icon Gentics GmbH, application No. 2005259335, under INID(71), correct the name to read Icon Genetics GmbH

27 August 2009 Application Accepted

  Published as AU-B-2005259335

24 December 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005259346-Detection of tuberculosis and infection by mycobacterium tuberculosis using HBHA

2005259329-Novel 2-substituted Dhomo-estra-1,3,5(10)-trienes as inhibitors of 17Beta-hydroxysteroid dehydrogenase type 1